Evaluation of severe acute respiratory syndrome coronavirus 2 monoclonal antibodies in high-risk solid organ transplant recipients across three major coronavirus disease 2019 variant waves.
Kristen E ZeitlerNicholas PiccicaccoMelissa O'NealJose MonteroAndrew MyersDaniel StrebigSarah NestlerLyndsey Bowman AngerKami KimPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2023)
Among SOTR outpatients with mild or moderate COVID-19 symptoms, early administration of mAb minimizes the need for hospital care. For patients requiring hospitalization, corticosteroids were common but patients experienced low rates of oxygen supplementation and ICU care. Use of mAbs in SOTRs should be considered early in the disease when therapy is available.
Keyphrases
- coronavirus disease
- respiratory syndrome coronavirus
- end stage renal disease
- healthcare
- sars cov
- newly diagnosed
- chronic kidney disease
- palliative care
- peritoneal dialysis
- intensive care unit
- emergency department
- stem cells
- mesenchymal stem cells
- physical activity
- patient reported outcomes
- mechanical ventilation
- health insurance
- sleep quality